Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jennifer Arrondeau"'
Autor:
Vincent Fallet, Pascal Rouby, Guido Ahle, Jennifer Arrondeau, Charles Naltet, Adeline Duflot-Boukobza, Françoise De Crozals, Hervé Lena, Alexis Cortot
Publikováno v:
Bulletin du Cancer. 109:477-490
Autor:
Vincent, Fallet, Pascal, Rouby, Guido, Ahle, Jennifer, Arrondeau, Charles, Naltet, Adeline, Duflot-Boukobza, Françoise, De Crozals, Hervé, Lena, Alexis, Cortot
Publikováno v:
Bulletin du cancer. 109(4)
The therapeutic arsenal for advanced ALK positive non-small cell lung cancer has been enriched by specific treatments targeting this molecular abnormality, with five molecules available, including lorlatinib, approved since July 2020. This treatment
Autor:
François Goldwasser, Eléonore De Guillebon, Hortense Gaultier De Saint Basile, Pascaline Boudou-Rouquette, Eric Tartour, Jennifer Arrondeau, Caroline Poisson
Publikováno v:
Bulletin du Cancer. 105:1202-1208
Physiological aging causes qualitative or quantitative immune system decline, also called immunosenescence. Older people with cancer are often ineligible for chemotherapy. The new immunotherapies (with PD1, PDL1 and CTLA4 checkpoint inhibitors) have
Autor:
François Goldwasser, Pascaline Boudou-Rouquette, Laure Cabanes, Anatole Cessot, Audrey Thomas-Schoemann, Anne Chahwakilian, Jérôme Alexandre, Benoit Blanchet, Jennifer Arrondeau, Galdric Orvoen, Camille Tlemsani, Olivier Huillard, Marie Bretagne, Romain Coriat
Publikováno v:
Bulletin du Cancer. 103:259-272
Angiogenesis inhibition is a major antitumor strategy that has emerged during the last decade. Oral tyrosine kinase inhibitors (TKI) targeting the VEGF receptor, including sunitinib, sorafenib, axitinib, regorafenib, pazopanib, and vandetanib reduce
Autor:
Hortense, Gaultier De Saint Basile, Caroline, Poisson, Jennifer, Arrondeau, Pascaline, Boudou-Rouquette, François, Goldwasser, Eric, Tartour, Eléonore, De Guillebon
Publikováno v:
Bulletin du cancer. 105(12)
Physiological aging causes qualitative or quantitative immune system decline, also called immunosenescence. Older people with cancer are often ineligible for chemotherapy. The new immunotherapies (with PD1, PDL1 and CTLA4 checkpoint inhibitors) have
Autor:
Jean-Charles Soria, Stéphane Champiat, Delphine Loirat, Jennifer Arrondeau, Benoît Rousseau, Nathalie Lemoine
Publikováno v:
Bulletin du Cancer. 101:31-39
Resume Les nouvelles immunotherapies dites immune checkpoints , comme l’ipilimumab, les anti-PD-1 ou PD-L1, ont donne des resultats prometteurs en monotherapie en oncologie medicale, a la fois dans les formes avancees de melanome, cancer du rein a
Autor:
Marie, Bretagne, Pascaline, Boudou-Rouquette, Olivier, Huillard, Audrey, Thomas-Schoemann, Anne, Chahwakilian, Galdric, Orvoen, Jennifer, Arrondeau, Camille, Tlemsani, Anatole, Cessot, Laure, Cabanes, Benoit, Blanchet, Romain, Coriat, Jérôme, Alexandre, François, Goldwasser
Publikováno v:
Bulletin du cancer. 103(3)
Angiogenesis inhibition is a major antitumor strategy that has emerged during the last decade. Oral tyrosine kinase inhibitors (TKI) targeting the VEGF receptor, including sunitinib, sorafenib, axitinib, regorafenib, pazopanib, and vandetanib reduce
Autor:
Benoît, Rousseau, Stéphane, Champiat, Delphine, Loirat, Jennifer, Arrondeau, Nathalie, Lemoine, Jean-Charles, Soria
Publikováno v:
Bulletin du cancer. 101(1)
New immunotherapies, also called "immune checkpoints", are promising and showed interesting antitumoral activities in particular in advanced setting of melanoma, clear cell renal cancer or non-small cell lung carcinoma. These treatments include ipili